ValuEngine upgraded shares of Akari Therapeutics PLC (NASDAQ:AKTX) from a strong sell rating to a sell rating in a research note published on Monday morning.
A number of other equities research analysts also recently issued reports on the company. Zacks Investment Research raised Akari Therapeutics PLC from a hold rating to a strong-buy rating and set a $4.00 price target for the company in a research report on Tuesday, August 29th. Canaccord Genuity reissued a buy rating and set a $15.00 price target (down previously from $33.00) on shares of Akari Therapeutics PLC in a research report on Monday, June 26th. Chardan Capital raised Akari Therapeutics PLC from a sell rating to a neutral rating and lowered their price target for the company from $6.50 to $6.00 in a research report on Wednesday, May 31st. Finally, William Blair reissued an outperform rating on shares of Akari Therapeutics PLC in a research report on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $7.17.
Shares of Akari Therapeutics PLC (NASDAQ AKTX) traded down 6.32% during trading on Monday, hitting $5.48. 56,441 shares of the stock traded hands. The firm’s market cap is $64.53 million. Akari Therapeutics PLC has a 52-week low of $3.18 and a 52-week high of $22.20. The stock has a 50 day moving average of $4.08 and a 200 day moving average of $7.24.
WARNING: This report was first reported by BBNS and is owned by of BBNS. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://baseballnewssource.com/markets/akari-therapeutics-plc-aktx-rating-increased-to-sell-at-valuengine/1635256.html.
A hedge fund recently bought a new stake in Akari Therapeutics PLC stock. Hikari Power Ltd purchased a new position in Akari Therapeutics PLC (NASDAQ:AKTX) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 60,012 shares of the biopharmaceutical company’s stock, valued at approximately $277,000. Hikari Power Ltd owned approximately 0.51% of Akari Therapeutics PLC as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 26.85% of the company’s stock.
Akari Therapeutics PLC Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with our FREE daily email newsletter.